Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group

AA van de Loosdrecht, R Ireland, W Kern, MG Della Porta, C Alhan, JS Balleisen, P Bettelheim, DT Bowen, K Burbury, L Eidenschink, M Cazzola, SSC Chu, M Cullen, JA Cutler, AM Drager, J Feuillard, P Fenaux, P Font, U Germing, D HaaseE Hellstrom-Lindberg, U Johansson, S Kordasti, MR Loken, L Malcovati, Jeroen te Marvelde, S Matarraz, T Milne, B Moshaver, GJ Mufti, V Nikolova, K Ogata, U Oelschlaegel, A Orfao, GJ Ossenkoppele, A Porwit, U Platzbecker, F Preijers, K Psarra, SJ Richards, D Subira, JF Seymour, V Tindell, T Vallespi, P Valent, Vincent van der Velden, DA Wells, TM de Witte, F Zettl, MC Bene, TM Westers

Research output: Contribution to journalArticleAcademicpeer-review

59 Citations (Scopus)

Abstract

An international working group within the European LeukemiaNet gathered, aiming to determine the role of flow cytometry (FC) in myelodysplastic syndromes (MDS). It was agreed that FC has a substantial application in disease characterization, diagnosis and prognosis. FC may also be useful in predicting treatment responses and monitoring novel and standard therapeutic regimens. In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS.
Original languageUndefined/Unknown
Pages (from-to)472-475
Number of pages4
JournalLeukemia & Lymphoma
Volume54
Issue number3
DOIs
Publication statusPublished - 2013

Cite this